"Hidden-Champion & Bilderbuch-Business: Figs & Arztkittel" - OAWS-Deep-Dive

Noah Leidinger hosts e-commerce expert Caro Juncker-Denoy for a detailed analysis of FIGS, a company that sells scrubwear (medical uniforms) directly to healthcare professionals. Noah opens by recounting a lost bet he made in 2022 predicting FIGS would outperform ON Running — a bet he lost as ON doubled while FIGS stagnated before its recent turnaround. FIGS was founded in 2013 by Trina Spear and Heifer Hessen, who identified that medical staff in the US were wearing unflattering scrubs and built a Lululemon-inspired premium brand, growing from selling in hospital parking lots to a $5 billion valuation at IPO in 2021.

Caro explains the core structural advantage of FIGS' D2C model: by eliminating wholesale and retail partners, who typically take 40–50% of end-customer price as a discount, FIGS operates with gross margins clearly above 60%, approaching 70% — levels more typical of luxury brands. This works particularly well in the US because medical staff purchase their own uniforms, unlike Germany where hospitals buy in bulk. FIGS built a strong love brand early on through a community ambassador program with ~200 doctors and nurses who had significant social followings and posted organically without being paid, just receiving free product.

The podcast examines FIGS' physical retail expansion, which they call 'community hubs' located near hospitals. Caro notes 40% of in-store customers are new and ~30% subsequently purchase online, suggesting the stores function more as brand and customer acquisition channels than pure sales drivers. FIGS enforces strict profitability requirements: stores must be profitable within one year and fully amortized within 24 months, which Caro views as a disciplined guardrail against overexpansion.

On international expansion, which represents 11% of revenue but is growing at twice the rate of the US core business, Caro expresses surprise at the momentum and credits FIGS with a good instinct for identifying markets with similar conditions — professionalized healthcare systems and high design affinity, such as South Korea and Japan. Germany is seen as harder due to the hospital bulk-purchasing model, though private practices, aesthetics clinics, and physiotherapy centers could be viable entry points. FIGS' planned entry into China via Tmall is highlighted as a pragmatic deviation from their pure D2C strategy, showing market-specific adaptability.

The B2B 'Teams' initiative — selling directly to hospitals and clinics rather than individual end consumers — is discussed as a potentially transformative but still nascent growth channel. Caro draws on her B2B consulting background to explain the longer, more complex sales cycles involved, but notes that once a clinic is won, it provides access to hundreds of employees with dramatically lower customer acquisition costs and extremely long customer lifetime value. She believes the workforce attraction angle — using premium scrubs as a recruitment and retention tool — could be relevant given the skilled worker shortage in healthcare.

FIGS' Olympic sponsorship of medical teams at the Paris Olympics is described as a 'brilliant marketing trick' — hyper-precise targeting of the exact professional demographic rather than broad consumer advertising, generating massive media coverage and a strong halo effect. Despite this and other marketing activities, Caro notes FIGS shows no apparent dependence on performance marketing (Meta, Google), which is highly unusual for a D2C brand and reflects the structural loyalty loop of a product that wears out and must be repurchased regularly.

On valuation, with FIGS at ~$2 billion market cap and $630 million in sales growing ~14% with only 2% cost growth, Noah notes the operating leverage is impressive. At a hypothetical 20% operating margin, they'd generate ~$140 million in profit, implying a ~14x earnings multiple. Caro cautions that 20% EBITDA margin is Inditex-level and a long way off, but acknowledges the simple product construction (basic cuts, few materials) leaves room for further cost efficiency. The cash position of $200 million — unusual for a startup-phase company — is seen as providing significant strategic freedom.

Finally, the discussion touches on competitive dynamics, with both guests agreeing that FIGS' position as market leader in a niche that doesn't reward second-place players creates a durable moat. The risk of capitulating to wholesale distribution — which destroyed Reebok's brand via Walmart — is flagged as something FIGS must resist. Caro mentions Oddity (personalized D2C makeup) as another exciting publicly listed D2C case, while noting the broader D2C landscape has few other strong examples, with Allbirds cited as a cautionary tale having been sold for just $40 million after a $10 billion peak valuation.